UK has gone from a leader to a laggard in biopharma, Eli Lilly CEO says ○
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Eli Lilly Chief Executive Officer Dave Ricks says a pullback in U.K. biopharmaceutical investments should send a message to U.S. policymakers.